Nathan Bahary

Mar 28, 2024 | mdpi.com | Faithlore Gardner |Zev A. Wainberg |Christos Fountzilas |Nathan Bahary

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Sep 14, 2023 | targetedonc.com | Nathan Bahary

Nathan Bahary, MD, PhD, division chief of medical oncology and director of clinical cancer research at the Allegheny Health Network (AHN) Cancer Institute, discusses how AHN has been able to combat the recent chemotherapy drug shortages, including those with cisplatin and carboplatin, seen nationwide. Transcription:0:10 | We've been very lucky at the Allegheny Health Network Cancer Institute.

Aug 11, 2023 | targetedonc.com | Nathan Bahary

Nathan Bahary, MD, PhD, division chief of medical oncology and director of clinical cancer research at the Allegheny Health Network Cancer Institute, discusses the ongoing challenge of chemotherapy drug shortages in the oncology field. Drug shortages are not a new concept, according to Bahary. However, it was exacerbated by the COVID-19 pandemic and now, necessary agents, including carboplatin and cisplatin, are currently short of supply.